OXFORD, UK - Oxford BioDynamics Plc (AIM: OBD), a biotech firm specializing in precision clinical diagnostics, has observed a notable change in its share price recently. The company, leveraging its EpiSwitch® 3D genomics platform, has acknowledged the volatility and reiterated its ongoing efforts to secure additional near-term funding, as initially announced on October 14, 2024.
The Board has expressed awareness of the current challenging market conditions, emphasizing that there is no certainty of a successful funding outcome. Oxford BioDynamics has projected the necessity for extra cash resources by early Q1 of 2025 and has committed to providing further updates when appropriate.
Oxford BioDynamics is known for its EpiSwitch® platform, which has produced two commercially available products: the EpiSwitch® PSE, a prostate screening test, and the EpiSwitch® CiRT, a response test for immuno-oncology checkpoint inhibitor treatments. These tests have significantly improved predictive accuracies in their respective applications.
The company operates globally with its headquarters and laboratories based in Oxford, UK, additional facilities in Maryland, USA, and a reference laboratory in Penang, Malaysia. It focuses on developing and commercializing precision clinical diagnostic tests for life-changing diseases, with ongoing research in oncology, neurology, inflammation, hepatology, and animal health.
This information is based on a press release statement issued by Oxford BioDynamics. The company's continued pursuit of funding is a response to the imperative need for financial resources to sustain its operations and research endeavors. As the situation unfolds, stakeholders are advised to stay tuned for upcoming announcements from the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.